In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


New Products In Brief

This article was originally published in The Rose Sheet

Executive Summary

MAC: Mineralize foundation is slated to launch Feb. 4 to MAC's permanent collection. The SPF 15 formula features a blend of 77 minerals "bio-fermented into a yeast extract" and firm's Multimineral Complex IV comprising potassium, magnesium, sodium and zinc. The foundation hydrates, reduces appearance of pores and lasts up to eight hours, according to the Estee Lauder Companies' unit. Mineralize comes in 23 shades, priced at $32 apiece. Firm also announces Riveting and Too Fabulous lines, rolling out Feb. 18 and March 4, respectively. Riveting pays homage to "sexy '80s fashion" with lipstick shades such as Metal Maven and Show Orchid and lipglass colors like Rock Out and True Babe, for $14 apiece. Eyeliner, powder blush and nail lacquer round out the line. MAC's Too Fabulous collection includes lip pencil and mineralize blush duo and permanently brings back MAC's Cremesheen Glass, sheer color lip glosses in shades such as Partial to Pink, Just Superb and Over Indulgence ($18 each)



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts